Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech To Benefit From 20% Corporate Rate, Tax-Free Foreign Transfers In Pending US Tax Bill

Executive Summary

Medical device firms will benefit from a Republican tax bill that has passed the full US House and a key Senate committee. The bill lowers the corporate tax rate to 20% from a maximum of 35%, treats foreign-earned intangible income at a favorably low rate of 12.5%, and permits tax-free transfers of intangible corporate property, such as patents, from foreign firms to US parents.

You may also be interested in...



Orthopedic Device Firms Lobby Hard On COVID-19 Relief And Reimbursements, Among Other Issues

Firms including Depuy Synthes, Medtronic Inc., and Zimmer Biomet Holdings Inc., spent thousands of dollars lobbying Congress last winter.

Medtech's Unfinished Business For Congress In 2018: What's Ahead

US Congress successfully pushed through a user-fee bill in 2017 to help smooth the regulatory path at FDA for medical devices and other products, but other efforts, including several industry priorities, remain undone. On top on the list, of course, is the effort to repeal the device excise tax. But legislation is also on the table to address diagnostics regulation, telehealth reimbursement, and medtech cybersecurity vulnerability, among other issues. Here is a look at the medtech landscape in Congress in 2018.

Medtech Supporter Sen. Orrin Hatch To Retire At Year's End

The medtech industry will lose a champion in Congress when Senate Finance Panel Chair Orrin Hatch, R-Utah, retires at the end of the 2018 congressional session. Author of the Americans with Disabilities Act and the Children's Health Insurance Program law, Hatch has been a perennial supporter of device-tax repeal, introduced market-based pricing for lab test reimbursements, and sponsored deep cuts in taxes for corporations in tax reform legislation signed into law just last month. Might former Massachusetts governor and failed 2008 US presidential candidate Mitt Romney run for the soon-to-be vacated seat?

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT121772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel